Platelet glycoprotein IIb/IIIa antagonists: Pharmacology and clinical developments

Anesthesiology

Volumn 96, Issue 5, 2002, Pages 1237-1249

  Warltier, David C ^b   Kam, Peter C A ^a   Egan, Mark K ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ABCIXIMAB; ALTEPLASE; ANESTHETIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; TIROFIBAN; XEMILOFIBAN;

ANESTHESIA MECHANISM; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; EMERGENCY TREATMENT; EPIDURAL ANESTHESIA; HEART MUSCLE ISCHEMIA; HUMAN; INTERVENTIONAL RADIOLOGY; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; META ANALYSIS; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; RISK BENEFIT ANALYSIS; SPINAL ANESTHESIA; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANIMALS; BLOOD PLATELETS; CLINICAL TRIALS; CORONARY ARTERY BYPASS; HUMANS; INTRAOPERATIVE COMPLICATIONS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0036237791     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200205000-00029     Document Type: Review

References (81)

1. Platelet-coagulant protein interactions
2. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
3. New antiplatelet agents: Platelet GPIIb/IIIa antagonists
4. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
5. Role of fibrinogen alpha and gamma chain sites in platelet aggregation
6. Integrins: A family of cell surface receptors
7. Platelet integrin GPIIb/IIIa: Structure-function correlations. An update and lessons from other integrins
8. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
9. Networking in the hemostatic system: Integrin alpha IIb/beta 3 binds prothrombin and influences its activation
10. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation
11. The platelet cytoskeleton regulates the affinity of the integrin alpha (IIb) beta (3) for fibrinogen
12. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
13. Platelet GPIIb-IIIa blockers
14. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin
15. Role of integrin alphaV/beta3 in vascular biology
16. Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: Cation displacement is involved in ligand binding
17. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents
18. A new murine monoclonal antibody reports an activation-dependant change in the confirmation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
19. Clinical pharmacology of eptifibatide
20. Lamifiban
21. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study
22. Orally active fibrinogen receptor antagonists. 2: Amidoximes as prodrugs of amidines
23. Will blocking the platelet save the diabetic?
24. Platelet glycoprotein IIb/IIIa inhibitors: Basic and clinical aspects
25. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary, angioplasty
26. Clinical challenges of platetet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia and retreatment
27. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischemic heart disease
28. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
29. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
30. Development of eptifibatide
31. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
32. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
33. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group: Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication
34. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
35. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade
36. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
37. Assessment of coronary angiograms prior to and after treatment with abciximab, and outcome of angioplasty in refractory unstable angina patients
38. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)
39. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
40. Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction
41. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
42. Meeting highlights: Highlights of the 48th Scientific Sessions of the American College of Cardiology
43. Platelet glycoprotein IIb/IIIa receptor antagonists: Current concepts and future directions
44. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
45. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
46. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
47. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
48. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: A randomized controlled trial
49. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators: Randomized efficacy study of tirofiban for outcomes and restenosis
50. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators
51. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
52. Lipid-lowering therapy after coronary revascularization
53. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
54. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
55. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
56. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
57. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy: Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis in myocardial infarction
58. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators: Evaluation of oral xemilofiban in controlling thrombotic events
59. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
60. Exit of platelet glycoprotein IIb/IIIa receptor inhibitors?
61. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
62. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis
63. A new type of pseudothrombocytopenia: EDTA-mediated aggregation of platetets bearing Fab fragments of a chimeric antibody
64. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists
65. Monitoring platelet GP IIb/IIIa antagonist therapy
66. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction
67. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
68. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
69. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors
70. A rapid and simple platelet function assay to assess GP IIb/IIIa receptor blockade
71. Rapid platelet-function assay: An automated and quantitative cartridgebased method
72. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention
73. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients
74. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery
75. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization: Management strategies for the cardiac surgeon
76. Guidelines for surgical standby for coronary angioplasty: Should they be changed?
77. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators: Evaluation prevention of ischemic complications
78. Coronary stenting and use of abciximab
79. Emergency coronary artery bypass graft surgery in abciximab-treated patients
80. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
81. Anticoagulation during cardiopulmonary bypass in patients with heparin induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoproteoin IIb-IIIa antagonist tirofiban